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Procurement of Human Tissues for Research Banking
in the Surgical Pathology Laboratory: Prioritization
Practices at Washington University Medical Center
Sandra A. McDonald,1 Rebecca D. Chernock,2 Tracey A. Leach,2 Ajaz A. Kahn,2
James H. Yip,2 Joan Rossi,3 and John D. Pfeifer2
Academic hospitals and medical schools with research tissue repositories often derive many of their internal
human specimen acquisitions from their site’s surgical pathology service. Typically, such acquisitions come from
appropriately consented tissue discards sampled from surgical resections. Because the practice of surgical pa-
thology has patient care as its primary mission, competing needs for tissue inevitably arise, with the requirement
to preserve adequate tissue for clinical diagnosis being paramount. A set of best-practice gross pathology
guidelines are summarized here, focused on the decision for tissue banking at the time specimens are macro-
scopically evaluated. These reflect our collective experience at Washington University School of Medicine, and
are written from the point of view of our site biorepository. The involvement of trained pathology personnel in
such procurements is very important. These guidelines reflect both good surgical pathology practice (including
the pathologic features characteristic of various anatomic sites) and the typical objectives of research bior-
epositories. The guidelines should be helpful to tissue bank directors, and others charged with the procurement
of tissues for general research purposes. We believe that appreciation of these principles will facilitate the
partnership between surgical pathologists and biorepository directors, and promote both good patient care and
strategic, value-added banking procurements.
Introduction
Barnes-Jewish Hospital is a large tertiary-care teachinghospital affiliated with Washington University School of
Medicine, with *55,000 surgical pathology specimens an-
nually. These specimens represent a complex variety of
common and rare tumors and other diseases of interest for
tissue procurement, and nondiseased tissues useful as con-
trols. Consequently, appropriately consented tissue discards
from this service are a valuable and commonly accessed re-
source, which support the Tissue Procurement Core (TPC) at
Washington University School of Medicine. The TPC con-
tains *400,000 diseased and normal specimens that are de-
rived from a wide variety of clinical trials and collection
protocols, of which one is the general banking protocol from
surgical pathology described here. The TPC supports a wide
variety of translational and other research programs at the
School of Medicine on a request-driven basis. Quality control
measures (among them histologic review, and DNA and
RNA quality assessments) are used when specimens are
disbursed, to assure that banked specimens have an accept-
able degree of integrity and readiness for use. During the
past year, *2000 new fresh-frozen tissue specimens were
accessioned into the biorepository from the general surgical
pathology laboratory.
Tissue banking procurements in the surgical pathology
setting come from surgical resections for diseased tissue,
whose quantity exceeds that needed for diagnosis and pa-
tient care. Nondiseased tissue may be included in the re-
sected specimen, and this is an opportunity for banking also.
Real-time specimen documentation and transport mecha-
nisms in place at Barnes-Jewish Hospital help maximize the
proportion of surgical specimens that go from the operating
room to the laboratory’s banking process in 30 min or less,
and thus can be snap-frozen with minimal degradation, and
maximum preservation of labile nucleic acids. Surgeons are
asked to send nonbiopsy specimens fresh whenever possible
(ie, without formalin in the container), to preserve the option
for banking. On arrival, specimens are prioritized for dis-
section jointly by the transport personnel and full-time pa-
thologists’ assistants, to further increase efficiency, and
minimize the time lapse. Since the actual transport time is
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usually well under 30 min, the prioritization mechanism and
pathologists’ assistant support ensures that even with time
for examination, margin ink, and so on, many specimens can
be sectioned and banked within 30 min.
Tissue for banking is typically taken when the specimen is
‘‘grossed in’’ (ie, specimen examined and dissected in the
gross room, a macroscopic description given, and sections
from key foci taken for microscopic evaluation). Essentially,
each tissue area or component within every specimen is
subjected to a 3-way decision: to sample for diagnosis (sur-
gical pathology), to sample for research banking, or to do
neither, in which case the tissue is typically placed in for-
malin and stored for several weeks before being discarded. A
2-methylbutane - 50C cryobath (Shandon Lipshaw Inc.,
Pittsburgh, PA) is present in proximity, so that freshly pro-
cured tissue for banking may be frozen rapidly, with mini-
mal time delay relative to its receipt in the laboratory.
Cryobath-frozen specimens are then transported in regular
intervals on dry ice to the tissue repository lab, by technol-
ogists from that lab.
Comprehensive summaries of gross evaluation and dis-
section practices exist for surgical specimens,1–3 yet these
rarely if ever reflect the point of view of biorepositories, who
naturally impose coexisting demands on the same tissue
resource, and who have interests and objectives that are of-
ten distinct from those of diagnostic surgical pathology
(Table 1). Because the latter is a complex science with its own
organ-specific standards of practice, the involvement of ap-
propriately trained personnel is required for good procure-
ment decisions (ie, where to take samples from, and how
much to take). Doing so will promote good patient care, by
ensuring that sufficient tissue remains for diagnosis, while
also enhancing the probability that the areas selected for
banking will be useful for research. For pathology trainees,
learning good tissue bank practices will enhance their gen-
eral surgical pathology skills, and help them learn to prior-
itize competing needs for tissues—a challenge likely to figure
prominently in research and practice environments of the
future.
At our institution, we have found it helpful to deliver
these gross room principles in a seminar offered to relevant
personnel in anatomic pathology (including new resident
trainees rotating on the service), as well as in an easily ac-
cessible written protocol. Pathologists’ assistants, residents,
and faculty pathologists contribute to specimen evaluation
and the procurement process, and decisions regarding di-
agnostic needs and tissue banking. Senior surgical patholo-
gists and tissue repository scientists are also available to
provide supervision and guidance as needed. In many cases,
the involvement of pathologists with subspecialty expertise
(a common resource at larger institutions such as ours)
contributes further value.
In this article, we summarize organ- and tissue-specific
guidelines that reflect our surgical pathology-based tissue
banking practice, with the expectation that the guidelines
will be useful to other groups and institutions as an in-
troduction to the field, or for comparison of best practices.
The emphasis here is on gross evaluation at the time the
surgical specimen arrives in the laboratory, when the de-
cision for tissue banking is made. Microscopic evaluations
that contribute to the science of tissue banking have been
separately described.4 The relevance of the various points
to other laboratories will of course depend on the focus
and objectives of one’s tissue repository. The principles
here mainly apply to the collection of tissue for general
future banking endeavors, where tissue that would other-
wise be discarded is banked, and then disbursed in a de-
identified fashion to investigators. Tissue procurements
driven by a clinical trial protocol, or as the sole objective
of a specified research study, can deviate somewhat
from these practices, depending on the stipulations in the
protocol.
At our institution, there is an emphasis on translational
studies requiring well-preserved snap-frozen tissue. Re-
positories that support mostly paraffin tissue-based work,
such as immunohistochemistry for protein localization, may
be able to employ less stringent procedures (especially re-
lating to collection timeframes and the need for unfixed
snap-frozen tissue) than those described here.
Discussion
There are several broad principles that characterize the
practice of general tissue banking at our institution. The most
important is that tissue for clinical diagnosis has the highest
priority. Thus, only tissue that is absolutely not needed for
clinical diagnosis should be taken for general banking. Once
a procured sample is accessioned into the biorepository, it
leaves the Clinical Laboratory Improvement Amendments/
College of American Pathologists–certified environment,
thereby hindering the ability to retrieve the tissue for clinical
diagnosis later. Another consideration is that banked tissue is
often subsequently chemically digested, such as for DNA or
RNA isolation, and so its microanatomic structure may be
lost by downstream procedures and not be able to be re-
constructed. Thus, it is important to make the right pro-
curement decisions in the grossing room initially.
Also, selection of the most optimal sample location (ie,
most representative of the disease process, having the least
hemorrhage or necrosis, etc.) yields the best downstream
results, and thus enhances the positive impact on transla-
tional and other research programs. Again, as with the first
principle, it is important to make the right decisions initially,
since procedural reversals such as the retrieval of tissue may
pose obstacles. For example, because surgically resected tis-
sue not submitted for banking or sectioned for diagnosis is
typically stored in formalin, it loses the research value that it
once had as fresh tissue.
A third overarching principle is that good, consistent
communication is needed between the clinical staff (includ-
ing surgeons) and the surgical pathology laboratory. This
is critically important for all aspects of good pathology
practice—including information on surgical specimens that
facilitates good diagnostic and procurement decisions.
In discussions with resident trainees and grossing room
personnel, we have found it helpful to emphasize the general
contraindications—both absolute and relative—that exist for
banking tissues from surgical pathology specimens. As a
corollary, any situation not fitting a contraindication is then
generally understood to be one where tissue can be procured
for banking.
Table 1 summarizes the key issues, which are described in
more depth below. Also, this table summarizes the often
competing viewpoints of surgical pathologists and tissue
banking personnel regarding these issues, and (in our view)
what represents the optimal resolution for them.
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Biopsies and other small cases where most
or all tissue must be processed for diagnosis
Most diagnostic biopsies, including gastrointestinal, gyne-
cologic, brain, bone marrow, and liver biopsies, fall in this
category. The reason is usually that all of the typically scarce
tissue biopsy must be evaluated histologically to provide an
accurate diagnosis. As a practical matter, these biopsies often
have limited utility for long-term research banking due to their
small volume, even aside from diagnostic considerations.
Table 1. Contrasting Viewpoints of Surgical Pathology and Tissue Banking for Gross Specimens
Situation/issue Surgical pathology viewpoint Tissue banking viewpoint Optimal reconciliation




Usually necessary to submit
and process all available
tissue for diagnosis
Some cases might have
research value, but others
are too small for long-term
banking value.
Except in unusual circum-
stances (eg, research
protocol), do not submit
these tissues for research
banking.






that might be valuable for
comparison purposes;
however, other adjacent
normal tissue may exist.
Diagnosis has priority;
surgical margin areas
should not be submitted
for banking. ‘‘Adjacent
normal’’ tissue, if desired,





Sampling these areas for mi-
croscopic examination may
be an interesting and im-




these areas are less likely to
be valuable since they may
contain a lower cellularity
% for the disease entity of
interest.
A histologic quality assur-
ance section can be done to
clarify the relationship of
gross to microscopic pa-
thology, and the usefulness
of the tissue for research.
Grossly visible areas of
necrosis, hemorrhage, and
adipose tissue
May be important to docu-
ment their presence in the
diagnostic process, but
they are usually not of pri-
mary interest
These areas are rarely of
research value.
Do not bank tissue from these




Very important to document
residual, viable neoplasm if
it is there
Tumors in this situation can
be valuable opportunities
for research banking
because of the insight they
offer in treatment
resistance.
Only sample tissue for
research banking if a
sufficiently sized, grossly
viable tumor mass is pres-
ent, in excess of what is
needed for diagnosis.
Specimens with collection
time delays or preserva-
tional deficits
Specimens with > 30 min of
warm ischemia time are
still useful for surgical pa-
thology evaluation.
Warm ischemia times of
> 30 min are generally most




tissues with varying levels





needed to corroborate a
previous biopsy diagnosis
For some disease entities, it is
necessary to extensively
sample resected tissue to
confirm or further evaluate
a previous biopsy
diagnosis.
Disease entities of this nature
are often interesting ones
for research banking.
Tissue for diagnosis has
priority; one should be
very cautious about sub-
mitting tissue for research
banking in this situation.
Generally, previously









Submission and evaluation of




Diseased tissue from these
areas might be interesting
for research banking
purposes, though useful
tissue can often be taken
from other regions that are
not critical for diagnosis.
Avoid sampling tissue for
banking from these impor-
tant foci, and take tissue
from elsewhere if available.
This requires good knowl-





needed before sections can
be taken and evaluated (eg,
osteosarcomas)
Decalcification treatments
may be problematic for the
downstream research value
of the tissue, especially
for samples that require
quick snap-freezing and
sectioning.
The optimal resolution here is
situation dependent. Best
research uses for tissues are
downstream applications
that are not hindered by
decalcification procedures.
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A related situation is tumors or disease types where, due to a
combination of relatively small specimen or lesion size, and the
need to detect focal but important findings that affect the di-
agnosis, it is standard practice to submit and evaluate all or
most of the tissue of interest for diagnosis. Testicular germ cell
tumors are one example; here, depending on the primary le-
sion’s size, it is often necessary to section and process all
available tumors for diagnosis, so as to detect the various
possible components of germ cell tumor (seminoma, mature
and immature teratoma, yolk sac tumor, and others). These
subtypes may exist in a wide variety of combinations, the
specifics of which may influence diagnosis and prognosis.5,6
Primary cutaneous malignant melanomas are another exam-
ple; here, unless the excised tumor tissue is very large, it is often
necessary to entirely process and evaluate it, to evaluate tumor
depth and thickness, growth pattern, histologic features, and
approach to margins—all of which contribute to the diagnosis,
and assist in prognosis and management.7,8 Key findings in
these categories could be present in only a small part of the
specimen, and one cannot risk that they might reside in the
sample submitted for research banking. By extension, this
principle also applies to any excised skin lesion for which
malignant melanoma is part of the differential diagnosis.8
Finally, incoming tissue samples may sometimes be in-
tended for a special study, such as immunofluorescence,
culture, or flow cytometry. Often these samples arrive in
special fixatives and/or with specific instructions. This rep-
resents an obvious further contraindication to banking.
Surgical margins of resection
Evaluation of surgical margins is a critical component of
surgical pathology practice, especially in oncology, for many
different specimens. We have described malignant melano-
mas, but in addition, margin evaluation is part of the exami-
nation of breast excisional biopsies, head and neck resections,
vulvectomies, and gastrointestinal tract and liver resections,
just to name a few categories.1 Because of the potential in-
fluence of margin evaluation on prognosis or subsequent
clinical management, one should obviously not sample mar-
gin tissues for banking. In some cases, it is necessary to return
to the gross specimen and re-sample margins after an initial
microscopic evaluation, thus raising the importance of prior-
itizing these areas for diagnostic purposes. It is important that
the surgeon inform the pathology personnel (through speci-
men orientation, marking sutures, face-to-face communica-
tion, or all of these) what areas constitute surgical margins, so
that these foci are not inadvertently sampled for banking.
The surgical margin of gross specimens typically needs to be
inked (on the exterior, grossly visible surface), before examina-
tion of the tissue’s interior and the taking of sections for diag-
nosis and banking. This is so that the margin surface(s) can be
identified in histologic sections later on. The ink will also help
one avoid margin areas when tissues for banking are chosen.
The application of such specimen ink is most commonly done
on receipt of a specimen into the surgical pathology laboratory.
Specimens with no grossly visible lesion, or where
diseased and nondiseased areas cannot be clearly
delineated grossly
This is a relative contraindication related to the common
objective of procuring tissues that are enriched for the disease
of interest. Samples where disease and nondiseased tissue
cannot be clearly delineated grossly (especially for tumor vs.
nonmalignant areas) are of less value since, if sampled purely
according to the gross appearance, they are less likely to have a
high cellular proportion for the entity of interest. Sometimes the
gross pathologist will have good choices available as to where
to sample tissue, but in other cases, gross obscuration of the
disease/nondisease interface is an intrinsic part of the pathol-
ogy. Examples of the latter include the alveolar growth pattern
of bronchioloalveolar carcinoma coexisting with pneumonic
consolidation,9,10 and prostatic carcinoma, which often shows
discrepancies between the gross appearance and the actual
extent of tumor.11 At our institution, for radical prostatectomies
done for malignancy, we take one representative section from
each lobe of the prostate for banking, rather than trying to
choose areas based on the gross appearance.
For any grossly ambiguous specimen, one can do a mi-
croscopic evaluation, either at the time of procurement or
later, and thereby judge the usefulness of the submitted area
for banking or research. Such quality assurance procedures,4
especially estimating the % cellularity for the tumor of in-
terest (ie, the percentage of nuclei in a section that are from
neoplastic cells), are in fact a common practice in our tissue
repository. A convenient situation arises when a frozen sec-
tion for diagnostic purposes is taken adjacent to the area in
question, thus providing a real-time indication as to the
usefulness of that same area for banking. Tissues for which
admixture of pathologic cells (or any entity of interest) and
background cells is unavoidable may often be enriched for
the former through laser capture microscopy.12
Some tumors, notably exocrine pancreatic adenocarci-
noma, produce a diffuse fibrotic appearance and a low tumor
% cellularity because of the intense desmoplasia that they
commonly elicit.13 Also, a few disease processes (Hashimoto’s
thyroiditis14 and some hematolymphoid tumors15) may in-
volve entire organs (eg, thyroid and spleen) diffusely and
relatively uniformly. These entities are useful for tissue
banking, and represent an exception to the guideline that a
distinct mass lesion or circumscribed abnormality should be
seen before procuring ‘‘abnormal’’ tissue for banking.
Grossly visible areas of primarily necrosis,
hemorrhage, or adipose tissue
Unless they are of primary scientific interest (which is
uncommon), these areas likely will contribute little scientific
value, since they are typically paucicellular and/or contain
degraded cells and nucleic acids. Therefore, they should not
be sampled for banking. Here, gross pathology skills are
important in delineating regions affected by these processes.
This may seem an obvious point, but in our experience,
samples retrieved from the archives of some commercial
tissue vendors sometimes show considerable amounts of
these adverse features, including necrosis.4
An interesting subcategory consists of chemotherapy- or
radiation-treated tumors with resulting treatment effect.
Here, tissue should not be submitted for banking if all that is
visible in the excised specimen is necrotic tissue with no
grossly visible tumor mass—microscopically visible residual
tumor might be missed, and the specimen might have little
research value anyway. However, if sufficiently sized, viable
residual neoplasm is present, it can represent a valuable
opportunity for tissue banking, because it can yield molec-
ular insights into treatment effect and/or resistance.16,17
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Specimens with collection time delays
or preservational deficits
Caution should be used in banking tissues as fresh-frozen
specimens that have been delayed > 30 min past their pro-
curement time in the operating room, though specimens with
longer times can be banked and the delay noted in the da-
tabase.18 This is because of the adverse effects that delayed
processing of fresh tissue may have, particularly on RNA
quality, and gene expression profiles.19 Naturally, surgical
pathology services with good documentation of collection
and transport times are better able to determine tissue ac-
ceptability based on such criteria. At our institution, we also
discourage the use of tissue for banking that has been freeze-
thawed, or frozen slowly (eg, fresh tissue placed directly into
a - 80C freezer), because of potential adverse effects on both
histologic and molecular preservation. For some tissues and
situations, RNA has been demonstrated to be stable after
delays of a few hours at room temperature before proces-
sing20; however, differences in RNA stability across various
tissue types limit the applicability of these studies.20 Quality
assessment procedures, such as those for RNA integrity,21
may be helpful if one is considering using frozen banked
tissue for which the collection or preservation conditions
were questionable.
Specimens where extensive tissue sampling
is needed to corroborate a previous diagnosis,
or to look for invasive tumor within established
atypia or in situ neoplasia
Practically speaking, a common surgical pathology objec-
tive is to confirm the presence and extent of disease in a sur-
gical specimen, and compare the findings to a previous biopsy
on which the decision for surgery was based, either in whole
or in part. For some disease entities, this may require generous
sampling and histological processing of surgical specimen
tissue, with relative contraindications to tissue banking.
Examples include ductal breast carcinoma in situ,22,23 lobular
breast carcinoma in situ,24 and atypical endometrial hyper-
plasia,25 which are often diagnosed in biopsy specimens.
Not only must the pathologist generously sample the surgi-
cally resected tissue to document the extent of the biopsy-
diagnosed disease, but the pathologist must also look for
occult invasive malignancies that are etiologically related (for
the entities above, these respectively are invasive ductal
breast carcinoma, invasive lobular breast carcinoma, and en-
dometrial adenocarcinoma). Such invasive foci are clinically
significant, but might be occasional or rare within a given
specimen. In some cases, it is necessary to return to the gross
specimen and submit more tissue for evaluation, based on
negative microscopic findings in a prior set of sections. Thus,
sampling for diagnosis in these situations may need to be
extensive, and procurements for tissue banking should pro-
ceed with significant caution, if at all. The size of the resected
specimen will influence this decision to some extent.
Preservation of other landmarks important
for surgical pathology evaluation
Surgical pathology evaluation is replete with organ- and
site-dependent landmarks that affect the pathologic stage,
influence the prognosis or advisability of further surgery, or
exert other consequences. It is important to avoid sampling
these landmark foci for banking, but instead preserve them
for clinical diagnosis. A complete discussion of all potentially
relevant topics is beyond the scope of this article; however,
the tissue repository director who works with a surgical
pathology service should be familiar with the more common
situations discussed below.
Capsular involvement for follicular thyroid masses and other
lesions. Thyroid masses are a common surgical specimen and
an attractive candidate for tissue banking. However, for en-
capsulated follicular masses—a key subtype—tissue banking
should proceed with great caution to avoid the capsule, since
detection of capsular invasion affects the diagnosis and
prognosis of the lesion, and thus the capsule must be entirely
submitted or at least extensively sampled.26,27 Thorough di-
agnostic sampling of thyroid follicular masses is important
also because of other changes, including vascular invasion
and tumor histopathology, that affect diagnosis and/or
prognosis.14,27 Diagnostic sampling is also important for the
documentation of capsular penetration for renal tumors, and
for certain encapsulated adrenal and salivary gland tumors1;
therefore, tissue banking efforts should avoid sampling these
areas.
Extranodal extension of tumor. Metastatic tumors, including
those in lymph nodes, are good candidates for tissue banking
because of the potential insight they offer into cancer bi-
ology. However, extranodal extension of such tumors (ie,
penetration of tumor through the lymph node capsule into
surrounding soft tissue) is a key prognostic anatomic land-
mark for various organs and sites.28,29 Therefore, such areas
need preferentially to be sectioned for clinical diagnosis (to
the extent they can be identified grossly) rather than in-
cluded in a tissue banking sample. Larger lymph nodes
containing metastatic tumor may have enough tissue for the
requisite surgical pathology sections, including the lymph
node capsular areas needed to assess the presence of extra-
nodal extension, while also allowing a banking specimen
from excess tissue elsewhere.
Areas of deepest tumor invasion. This is a key landmark that
affects staging and prognosis for a variety of tumors, in-
cluding skin, gastrointestinal tract, urinary bladder, and en-
dometrium.30 Thus, areas of deepest invasion should be
sectioned for diagnosis and documentation purposes, and
not used for tissue banking procurement. This of course re-
quires careful gross dissection skills in identifying and sec-
tioning the relevant areas.
Stalk in colonic adenomatous polyps. Adenomatous polyps of
the colon are a very common surgical pathology specimen.
Sometimes they are large enough to be tempting as a tissue
banking specimen. However, the pedunculated stalk of these
polyps should not be inadvertently sampled for banking,
since incipient cancers in an otherwise benign-appearing
polyp can be detected in this area. Such a finding may es-
tablish a need for close clinical follow-up and/or more ag-
gressive management, especially in situations where the
invasive tumor is deep within the stalk, shows lymphvas-
cular invasion, or reaches the stalk’s surgical margin.31,32
Laryngeal dissections. Though far from the only site in this
category, the larynx deserves mention because of the large
number of anatomic landmarks, for which tumor involve-
ment (if present) needs to be sectioned for staging and doc-
umentation purposes: false and true cords, aryepiglottic folds,
ventricles, subglottic extension, paraglottic and preepiglottic
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space and cartilage invasion, and others.1 Thus, tissue
taken for banking should not obscure the demonstration
of these features in sections taken for surgical pathology
evaluation.
Bony tumors requiring decalcification
Some tumors produce bone as an intrinsic part of their
growth, either due to their primary lineage (eg, osteosarco-
ma) or as an unusual metaplastic feature of an otherwise soft,
cellular tumor (eg, metaplastic breast carcinoma). Depending
on the tissue’s resulting hardness and nature of the intended
studies, taking samples for banking may be problematic—
especially if immediate snap-freezing and subsequent tissue
sectioning is desired, since decalcification steps are typically
needed to soften the tissue sufficiently for research proce-
dures. The usefulness of such tissue for fixed paraffin-tissue
banking can be compromised by the possible denaturation
or loss of proteins of interest from the decalcification
procedure.33–35
Conclusion
Consideration of surgical pathology practice require-
ments, especially in a tissue- and situation-dependent fash-
ion, will enhance the quality of both clinical diagnosis and
the utility of appropriately consented specimens that are
procured and accessioned into a research tissue repository
from the surgical pathology laboratory. Tissue bank directors
should establish good working relationships with surgical
pathologists, and understand the key principles and chal-
lenges of the latter group’s practice. The points summarized
in this article may be useful as an introduction to the field, as
a substrate for strategic operating protocols, or as informa-
tion for trainees. Optimal implementation requires the in-
volvement of trained pathology personnel within the
laboratory. The contraindications listed here notwithstand-
ing, there are many useful tissue banking specimens that can
be procured from a typical surgical pathology service, and
we encourage tissue banks to fully utilize such sources when
possible. We invite comparison of our best practices with
those at other institutions.
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